The commercial launch also included the sensor-enabled Advisor FL circular mapping catheter, Abbott said. The system, which won 510(k) clearance from the FDA in December 2016, was used for the 1st time commercially at Salt Lake City’s Intermountain Medical Center, Abbott said.
“The new EnSite Precision cardiac mapping system allows better 3-dimensional images of the arrhythmias in the heart, which improve the accuracy of what we see during the procedure so we can more precisely treat the patient,” Day said in prepared remarks. “We were excited to perform the inaugural case in the U.S., and we continue to utilize the system daily to provide the best patient care possible.”
“This next generation technology was designed in collaboration with some of the world’s leading electrophysiologists so that they can quickly and precisely identify the source and substrate source of a patient’s irregular heartbeat,” added VP Dr. Srijoy Mahapatra. “We expect the EnSite Precision cardiac mapping system to become the new standard for identifying abnormal heart rhythms when tailoring treatment for patients suffering from arrhythmias.”
Last October, Little Canada, Minn.-based St. Jude said it’s installed more than 100 EnSite Precision systems in Europe after winning CE Mark approval in January 2016.